| Tammy Brooks Garber, MS | |
|
2155 Electric Rd, Suite C, Roanoke, VA 24018-2302 | |
| (540) 774-4441 | |
| (540) 774-3393 |
| Full Name | Tammy Brooks Garber |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 39 Years |
| Location | 2155 Electric Rd, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174680136 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 2201000329 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hearing Health Associates Pc | 5395895700 | 2 |
News Archive
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).
Patients developing AFib after TAVR are at higher risk of death, stroke and heart attack compared to patients who already had AFib prior to the procedure, according to a study today in JACC: Cardiovascular Interventions. The paper is the first nationwide examination of patients who developed AFib for the first time following TAVR.
Homes in low-income and affluent communities in California both had similarly high levels of endocrine disruptors, and the levels were higher in indoor air than outdoor air, according to a new study believed to be the first that paired indoor and outdoor air samples for such wide range (104) of these substances. The study appears in ACS' Environmental Science & Technology, a semi-monthly journal.
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA.
› Verified 7 days ago
| Provider Name | Hearing Health Associates Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1427147198 PECOS PAC ID: 5395895700 Enrollment ID: O20090605000195 |
News Archive
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).
Patients developing AFib after TAVR are at higher risk of death, stroke and heart attack compared to patients who already had AFib prior to the procedure, according to a study today in JACC: Cardiovascular Interventions. The paper is the first nationwide examination of patients who developed AFib for the first time following TAVR.
Homes in low-income and affluent communities in California both had similarly high levels of endocrine disruptors, and the levels were higher in indoor air than outdoor air, according to a new study believed to be the first that paired indoor and outdoor air samples for such wide range (104) of these substances. The study appears in ACS' Environmental Science & Technology, a semi-monthly journal.
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tammy Brooks Garber, MS 2155 Electric Rd, Suite C, Roanoke, VA 24018-2302 Ph: (540) 774-4441 | Tammy Brooks Garber, MS 2155 Electric Rd, Suite C, Roanoke, VA 24018-2302 Ph: (540) 774-4441 |
News Archive
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).
Patients developing AFib after TAVR are at higher risk of death, stroke and heart attack compared to patients who already had AFib prior to the procedure, according to a study today in JACC: Cardiovascular Interventions. The paper is the first nationwide examination of patients who developed AFib for the first time following TAVR.
Homes in low-income and affluent communities in California both had similarly high levels of endocrine disruptors, and the levels were higher in indoor air than outdoor air, according to a new study believed to be the first that paired indoor and outdoor air samples for such wide range (104) of these substances. The study appears in ACS' Environmental Science & Technology, a semi-monthly journal.
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA.
› Verified 7 days ago
Kevin E Mccurdy, CCC-A Audiologist Medicare: Medicare Enrolled Practice Location: 325 Elm Ave Se, Roanoke, VA 24013 Phone: 540-343-5567 | |
Kristina S Miller, AU.D., CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3 Riverside Cir, Roanoke, VA 24016 Phone: 540-224-5170 | |
Mrs. Heather B Dickey, MSCCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2030 Colonial Ave Sw, Roanoke, VA 24015 Phone: 540-343-0165 Fax: 540-343-4664 | |
Roanoke Valley Speech And Hearing Center, Inc. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2030 Colonial Ave Sw, Roanoke, VA 24015 Phone: 540-343-0165 Fax: 540-345-4664 | |
Michelle Ann Ickes, PH.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2030 Colonial Ave Sw, Roanoke, VA 24015 Phone: 540-343-0165 | |
Hearing Health Associates, Pc Audiologist Medicare: Medicare Enrolled Practice Location: 2155 Electric Rd, Suite C, Roanoke, VA 24018 Phone: 540-774-4441 Fax: 540-774-3393 |